+91-8668442535

Bacterial Vaginosis Drugs Market By Type (Rx, OTC) By Application (Hospital, Pharmacy, Others) - Growth, Future Prospects & Competitive Analysis, 2016 - 2028

According to the Centers for Disease Control and Prevention, the prevalence of bacterial vaginosis is 18.8 percent among celibate women, 25 percent among pregnant women, and 31.7 percent among women who have never been pregnant. The risk factors associated with the disease etiology of bacterial vaginosis are pelvic inflammatory disease, preterm delivery of infants, urinary tract infection, and sexually transmitted diseases (STD). The products in the pipeline in phase 3 for the treatment of bacterial vaginosis are Metronidazole oral tablets, 500 mg; 1% SPL7013 Gel; GDC-229; Clindamycin, 100 mg; Ketoconazole, 400 mg; and the association of metronidazole, nystatin, and dexamethasone.

Oral routes comprise Metronidazole, Tinidazole, Clindamycin, and Secnidazole. Metronidazole, clindamycin, and normal pH restoration gels are used topically. Canesbalance and VivaGel® are two sub-categories of normal pH restoration gels. Recent trends prevailing in the bacterial vaginosis drug market are understood by the inclusion of market size and forecast in the scope of the report.

Following geographical segmentation, their major countries have been included in the scope of the report:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

To understand the country's cross-sectional market of bacterial vaginosis drugs, a market estimate and forecast for the period 2015-2025 have been reported for the major countries included in the regional segments.

The competitive landscape and attractive investment proposition give a clear idea of the first-line treatment drugs employed for the treatment of bacterial vaginosis and the product pipelines of key manufacturers engaged in the bacterial vaginosis treatment industry. A collaborative partnership between the key players to promote recently approved drugs is mentioned in the company profiles considered for the bacterial vaginosis drug market. The major players in the global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited, and Symbiomix Therapeutics.

Based on the route of administration, the bacterial vaginosis drugs market is categorized into:

  • Oral Route
    • Metronidazole
    • Tinidazole
    • Clindamycin
    • Secnidazole
  • Topical Route
    • Metronidazole
    • Clindamycin
  • Normal pH Restoration Gels
      • VivaGel®
    • Canesbalance

Bacterial vaginosis is the most common type of vaginal infection caused by a pH imbalance in the vaginal environment, which is triggered by an imbalance between the good microflora of Lactobacillus species and the bad microflora of Gardnerella vaginalis. The clinical manifestation of bacterial vaginosis is asymptomatic in nature, with the symptoms recurring after a few days of earlier treatment with antibiotics. The treatment regimen is designed with drug formulations, either oral or topical, that is efficient in eliminating the colonization of Gardnerella vaginalis. Currently, antibiotics are the preferred treatment regimen for bacterial vaginitis, employing drugs such as metronidazole, clindamycin, and tinidazole. Broad-spectrum antimicrobial activity, e.g., secnidazole (Solosec), and immediate symptomatic relief make antibiotic treatment the largest revenue generator. Metronidazole is considered more beneficial than clindamycin for the treatment of bacterial vaginosis as it is safe during pregnancy and does not eliminate the colonization of the good bacteria Lactobacillus species. Normal pH restoration gels, e.g., Canesbalance (Bayer AG) and VivaGel® (Starpharma Holdings), will have impressive growth in the near future as they address the key problem of microflora imbalance in the vaginal environment and have relatively few side effects in comparison to antibiotics. The prominent players in the bacterial vaginosis drugs market are Abbott Laboratories, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited, and Symbiomix Therapeutics.

For the purpose of this study, the global bacterial vaginosis drugs market is categorized into the following regional and country-specific markets:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

The Centers for Disease Control and Prevention's 2015 statistics have reported the prevalence of bacterial vaginosis in the North American female population to be around 84 percent with no symptoms. Because of the rising prevalence in African American and Hispanic women, an effective dosage regimen that provides immediate relief is required. The domicile of key pharmaceutical industries engaged in the production and sale of antibiotics contributes to the dominance of North America in the bacterial vaginosis drug market. The European market is driven by the rising prevalence of bacterial vaginosis due to an increase in the lifetime number of sexual partners. The recent influx of North African refugees with a history of bacterial vaginosis has increased the treatment burden on the European healthcare segment. Asia Pacific will enjoy superlative growth in the bacterial vaginosis drug market due to the huge revenue generated by the generic antibiotic drug market. Poor socioeconomic conditions and a lack of awareness regarding personal hygiene also contribute to the growth of the Asia Pacific bacterial vaginosis drug market. Increasing disposable income and health awareness campaigns regarding self-hygiene by healthcare agencies such as the World Health Organization and Red Cross will proliferate the bacterial vaginosis drug market in Latin America, the Middle East, and Africa.

Frequently Asked Questions:

The COVID-19 outbreak negatively impacted the market due to the transformation of the healthcare system to manage COVID-19 has resulted in medication launch cancellations and clinical trial delays.

North America accounted for the major revenue share in the bacterial vaginosis drug market.

The major drivers responsible for the market's growth include the rising frequency of bacterial infections and vaginosis, increased research and development efforts, and awareness about women's health.

The Rx segment had a major share in the global market in 2021.

The hospital segment had a major share in the global market.

Bacterial Vaginosis Drugs Market Scope

Report Attribute Details
Market Value in 2021 USD 872.6 million
Market Value in 2028 USD 1136.3 million
CAGR 4.5%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2022
Category:  Pharmaceuticals
Report ID:   58853
Report Format:   PDF
Pages:   120
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support